All In Biotech

NDA 207078 · Astrazeneca

Lokelma

Sodium Zirconium Cyclosilicate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Feb 8, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

May 18, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

35

17 Phase 3, 5 recruiting

FAERS reports

4,008

3,277 serious, 1,441 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2026.

LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) and Clinical Studies (14) ] . LOKELMA is a potassium binder indicated for the treatment of hyperkalemia in adults. ( 1 ) Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. ( 1 )

Mechanism: LOKELMA (sodium zirconium cyclosilicate) is a non-absorbed zirconium silicate that preferentially captures potassium in exchange for hydrogen and sodium. In vitro , LOKELMA has a high affinity for potassium ions, even in the presence of other cations such as calcium and magnesium. LOKELMA increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, thereby lowering serum potassium levels.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • LOKELMA · SODIUM ZIRCONIUM CYCLOSILICATE 5GM/PACKET · FOR SUSPENSION, ORAL · Prescription · TE AB
  • LOKELMA · SODIUM ZIRCONIUM CYCLOSILICATE 10GM/PACKET · FOR SUSPENSION, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Zirconium Cyclosilicate" as an intervention, any sponsor and status, largest first.

All 35 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death1,159
  • blood potassium increased206
  • hyperkalaemia186
  • diarrhoea180
  • constipation127
  • off label use127
  • cardiac failure95
  • nausea94
  • renal failure94
  • vomiting89
  • acute kidney injury84
  • pneumonia80

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201810
2019112
2020200
2021262
2022387
2023541
2024828
2025863
2026805

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lokelma (Sodium Zirconium Cyclosilicate)

2024 spending

$239M

Beneficiaries

116,877

334,671 claims

Per beneficiary

$2,045

$26.66 per unit

View as table
YearSpending
2020$48,507,096
2021$100,112,117
2022$160,327,812
2023$205,055,771
2024$239,002,704

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 46 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.